Your browser is no longer supported. Please, upgrade your browser.
Settings
INFI [NASD]
Infinity Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.68 Insider Own2.35% Shs Outstand88.64M Perf Week-0.65%
Market Cap280.33M Forward P/E- EPS next Y-0.58 Insider Trans-73.07% Shs Float78.21M Perf Month-13.07%
Income-40.50M PEG- EPS next Q-0.12 Inst Own38.40% Short Float1.51% Perf Quarter-19.90%
Sales1.70M P/S164.90 EPS this Y18.10% Inst Trans8.02% Short Ratio0.31 Perf Half Y152.89%
Book/sh-0.36 P/B- EPS next Y-9.40% ROA-84.30% Target Price- Perf Year191.43%
Cash/sh0.37 P/C8.22 EPS next 5Y- ROE319.10% 52W Range0.78 - 5.98 Perf YTD44.34%
Dividend- P/FCF- EPS past 5Y23.70% ROI167.40% 52W High-47.16% Beta2.26
Dividend %- Quick Ratio3.30 Sales past 5Y-56.40% Gross Margin39.70% 52W Low305.13% ATR0.27
Employees23 Current Ratio3.30 Sales Q/Q33.30% Oper. Margin- RSI (14)50.63 Volatility8.79% 8.17%
OptionableYes Debt/Eq- EPS Q/Q17.20% Profit Margin- Rel Volume0.18 Prev Close3.06
ShortableYes LT Debt/Eq- EarningsMar 16 AMC Payout- Avg Volume3.83M Price3.16
Recom2.10 SMA200.45% SMA50-3.43% SMA20051.17% Volume166,180 Change3.27%
Mar-18-21Initiated Truist Buy $12
Feb-18-21Initiated Piper Sandler Overweight $7
Feb-05-21Upgrade JP Morgan Underweight → Neutral
Jun-27-19Initiated Oppenheimer Outperform
Jan-04-19Initiated B. Riley FBR Buy $3
Nov-12-18Downgrade Wells Fargo Outperform → Market Perform
Nov-12-18Downgrade JP Morgan Neutral → Underweight
Oct-12-17Upgrade Wells Fargo Market Perform → Outperform
Aug-10-16Reiterated Wedbush Neutral $1.25 → $1
Jun-15-16Downgrade Wells Fargo Outperform → Market Perform
Jun-15-16Downgrade RBC Capital Mkts Outperform → Sector Perform $12 → $2
Jun-15-16Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-15-16Downgrade Jefferies Buy → Hold
Jun-14-16Downgrade JP Morgan Overweight → Neutral
Jun-14-16Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jun-14-16Downgrade FBR Capital Outperform → Mkt Perform $15 → $2
Mar-02-16Initiated FBR Capital Outperform $15
Feb-25-16Reiterated Wedbush Neutral $9 → $8
Sep-21-15Upgrade Morgan Stanley Equal-Weight → Overweight
Aug-07-15Reiterated RBC Capital Mkts Outperform $18 → $15
Apr-13-21 08:59AM  
Mar-29-21 03:22AM  
Mar-19-21 08:47AM  
Mar-16-21 05:35PM  
04:35PM  
04:05PM  
02:30PM  
Mar-10-21 08:35AM  
Mar-09-21 04:01PM  
Mar-02-21 08:35AM  
Feb-20-21 07:40AM  
Feb-18-21 10:02AM  
08:30AM  
Feb-12-21 08:30AM  
08:10AM  
Feb-11-21 04:01PM  
12:38PM  
09:25AM  
09:16AM  
07:15AM  
Feb-10-21 04:05PM  
Jan-20-21 12:00PM  
Jan-15-21 08:35AM  
Jan-11-21 08:53AM  
08:05AM  
Jan-07-21 10:51AM  
08:35AM  
Jan-06-21 09:11AM  
Dec-27-20 02:34AM  
Dec-09-20 12:25PM  
09:10AM  
Dec-07-20 07:35AM  
Dec-02-20 09:47PM  
Nov-17-20 09:22AM  
Nov-12-20 05:53AM  
Nov-09-20 06:35PM  
05:14PM  
04:05PM  
02:30PM  
08:05AM  
Nov-02-20 04:05PM  
Oct-28-20 12:33PM  
Oct-11-20 10:58AM  
Sep-30-20 09:15AM  
Sep-29-20 07:35AM  
Sep-04-20 08:05AM  
Aug-11-20 08:49AM  
08:39AM  
Aug-10-20 03:30PM  
Jul-30-20 06:30PM  
04:05PM  
Jul-23-20 07:35AM  
Jul-08-20 08:22AM  
Jun-10-20 03:46PM  
11:30AM  
08:45AM  
Jun-04-20 08:35AM  
May-12-20 12:48PM  
May-11-20 08:55AM  
07:35AM  
May-04-20 07:35AM  
Apr-28-20 12:33PM  
Apr-20-20 07:59AM  
Apr-10-20 12:00PM  
Apr-07-20 07:35AM  
Apr-02-20 11:30AM  
Mar-26-20 06:07PM  
09:35AM  
Mar-25-20 07:35AM  
Mar-17-20 01:49PM  
07:35AM  
Mar-04-20 03:31PM  
Mar-03-20 05:35PM  
04:05PM  
Feb-25-20 07:35AM  
Jan-23-20 08:34AM  
Jan-13-20 07:35AM  
Jan-09-20 09:00AM  
07:35AM  
07:05AM  
Dec-20-19 06:23PM  
Nov-09-19 10:24PM  
Oct-31-19 12:45PM  
Oct-30-19 06:25PM  
04:03PM  
Oct-23-19 08:33AM  
Oct-08-19 10:02AM  
09:18AM  
Sep-05-19 10:24AM  
Sep-04-19 08:32AM  
Sep-03-19 08:32AM  
Aug-29-19 09:31AM  
Aug-22-19 04:03PM  
Aug-03-19 07:50AM  
Jul-31-19 10:16AM  
Jul-30-19 08:55AM  
07:32AM  
Jul-23-19 08:32AM  
Jun-24-19 08:33AM  
Jun-06-19 09:31AM  
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 1/1b clinical trials for the treatment of triple negative breast cancer, solid tumors, and ovarian cancer. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BVF PARTNERS L P/IL10% OwnerJan 22Sale4.145,848,52024,205,855686,974Jan 26 05:27 PM